A total of 321 patients with metastatic prostate cancer in relapse after first-line endocrine therapy entered a Phase III international multicenter study ( recruitment from February 1992 to August 1994 ) comparing liarozole ( 300 mg two times daily ) with CPA ( 100 mg two times daily ) .
